Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%

6. oktober 2026 opdateret af: Eye Research Associates, LLC

A Clinical Evaluation of Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%

Dry Eye Disease is a multifaceted condition which has symptoms such as eye dryness, burning, and stinging sensation in the eyes. As well as clinical diagnosis such as a decreased ability to create tear film. Despite improvements in Contact Lenses (CL) DED still is responsible for a large percentage of CL dropouts due to discomfort. Thus, the purpose of this study is to determine if acoltremon 0.003% can improve the frequency and severity of DED symptoms in CL wearers.

Studieoversigt

Status

Ikke rekrutterer endnu

Intervention / Behandling

Detaljeret beskrivelse

This 1 month 3 visit, single arm open label study aims to determine if acoltremon 0.003% can improve the frequency and severity of Dry Eye Disease (DED) symptoms in CL wearers. DED is a multifactorial condition that can cause stinging, burning sensation or dry eyes. It can also have clinically significant findings such as decreased tear production (aqueous-deficient DED) or increased tear evaporation (evaporative DED). Conditions like this often lead to discomfort, and thus individuals to drop out of wearing contact lenses. With nearly 20% of CL dropouts annually being due to discomfort.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

50

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Chris Lievens, OD, PhD
  • Telefonnummer: 901-481-5699
  • E-mail: clievens@sco.edu

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • • Adult subjects who are ≥18 years of age.

    • Best corrected CL visual acuity of 0.1 Logarithm of the Minimum Angle of Resolution (logMAR) or better in both eyes (Snellen equivalent 20/25).
    • Willing to wear a new pair of CLs to the baseline study visit.
    • Daily, soft, frequent replacement CL wearer (daily disposable, bi-weekly, or monthly CLs).
    • An Eye Dryness VAS score of ≥40.
    • CLDEQ-8 scores (CLDEQ-8 scores ≥12).
    • A score of >7 dots on the Lexitas NEI staining scale (grade 1 in a single sector on the 5-sector scale).
    • Habitual wearers of soft CLs for a minimum of 5 days per week for 6 hours or more per day during the month prior to enrollment.
    • Willing to maintain habitual soft CL wear of a minimum of 5 days per week for 6 or more hours per day for the 1 month duration of the study.
    • Habitual CLs have an acceptable fit (good centration, movement, and coverage

Exclusion Criteria:

  • Any history of acoltremon 0.003% use.
  • Are currently an overnight CL wearer.
  • Are currently hard or scleral CL wearers.
  • Have known systemic health conditions that are known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome).
  • Have a history of ocular surgery within the past 12 months.
  • Have a history of viral eye disease that may confound study results.
  • Have a history of severe ocular trauma, active ocular infection or inflammation.
  • Have ever used isotretinoin-derivates (e.g., Accutane).
  • Are currently taking ocular medications (including topical glaucoma medication) or plan to during the study.
  • Have had a physical meibomian gland treatment withing 1 month of enrollment (iLux, Lipiflow, Radio Frequency and IPL with manual expressions, microblepharoexfoliation etc.).
  • Have used a prescription DED medication in the last 1 month.
  • Unwilling to agree to discontinue artificial tear use the day before enrollment and throughout the study.
  • Have a condition or in a situation, which in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation.
  • Are pregnant or breast feeding.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: acoltremon 0.003%

participants will be provided with acoltremon 0.003% and instructed to use it twice a day.

Acoltremon 0.003% (TRYPTYR; Alcon Laboratories; Fort Worth, TX, USA) was recently approved by the US Food and Drug Administration (FDA) as the first transient receptor potential melastatin (TRPM8) agonist for the treatment of DED. Acoltremon 0.003% is dosed twice a day

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Eye Dryness Score (VAS) at 4 weeks compared to baseline
Tidsramme: 1 month

participants will be asked to evaluate their eye dryness using a VAS scale with higher numbers indicating greater comfort.

1 month

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Eye Dryness Score (VAS) at 2 weeks compared to baseline
Tidsramme: two weeks

participants will be asked to complete an eye dryness visual analog scale with higher numbers indicating greater comfort

two weeks
CL End of day comfort VAS
Tidsramme: 4 weeks

participants will be asked to complete a contact lens comfort visual analog scale with higher numbers indicating greater comfort

4 weeks
CL End of day comfort VAS
Tidsramme: 2 weeks

participants will be asked to complete a contact lens comfort visual analog scale with higher numbers indicating greater comfort

2 weeks
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
Tidsramme: 1 month

participants will be asked to complete the CLDEQ-8 questionnaire with lower scores indicating more comfort

1 month
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
Tidsramme: 2 weeks

participants will be asked to complete the CLDEQ-8 questionnaire with lower scores indicating more comfort

2 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

10. oktober 2026

Primær færdiggørelse (Anslået)

14. februar 2027

Studieafslutning (Anslået)

21. februar 2027

Datoer for studieregistrering

Først indsendt

24. september 2026

Først indsendt, der opfyldte QC-kriterier

24. september 2026

Først opslået (Faktiske)

30. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IRB000673-Acoltremon dry eye

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

IPD-planbeskrivelse

An abstract describing the primary outcome will be submitted for ARVO 2027, and a manuscript on the same topic will be submitted to Contact Lens & Anterior Eye or similar publication. An abstract related to the Likert survey results will be submitted to Optometry's Meeting 2027

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner